Loxo Oncology, Inc. (NASDAQ:LOXO) major shareholder Aisling Capital Iii Lp sold 500,000 shares of the firm’s stock in a transaction dated Wednesday, November 22nd. The stock was sold at an average price of $75.00, for a total transaction of $37,500,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Loxo Oncology, Inc. (NASDAQ:LOXO) opened at $73.62 on Thursday. Loxo Oncology, Inc. has a 12-month low of $25.25 and a 12-month high of $95.92.

Several research analysts recently commented on the stock. BidaskClub raised shares of Loxo Oncology from a “sell” rating to a “hold” rating in a research note on Saturday, August 12th. Zacks Investment Research raised shares of Loxo Oncology from a “hold” rating to a “buy” rating and set a $82.00 price target on the stock in a research note on Wednesday, August 9th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $94.00 price target (up previously from $71.00) on shares of Loxo Oncology in a research note on Thursday, August 10th. Citigroup reduced their price target on shares of Loxo Oncology from $112.00 to $108.00 and set a “buy” rating on the stock in a research note on Thursday, November 16th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $75.00 price target on shares of Loxo Oncology in a research note on Thursday, August 3rd. Two investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $90.57.

A number of hedge funds and other institutional investors have recently bought and sold shares of LOXO. Quantbot Technologies LP purchased a new position in Loxo Oncology during the 3rd quarter valued at about $122,000. Ameritas Investment Partners Inc. increased its position in Loxo Oncology by 31.3% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 1,758 shares of the biopharmaceutical company’s stock valued at $141,000 after purchasing an additional 419 shares during the period. Legal & General Group Plc increased its position in Loxo Oncology by 8.4% during the 1st quarter. Legal & General Group Plc now owns 3,682 shares of the biopharmaceutical company’s stock valued at $154,000 after purchasing an additional 284 shares during the period. BNP Paribas Arbitrage SA increased its position in Loxo Oncology by 4,388.0% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,244 shares of the biopharmaceutical company’s stock valued at $180,000 after purchasing an additional 2,194 shares during the period. Finally, Cambridge Investment Research Advisors Inc. purchased a new position in Loxo Oncology during the 3rd quarter valued at about $212,000.

WARNING: “Insider Selling: Loxo Oncology, Inc. (LOXO) Major Shareholder Sells $37,500,000.00 in Stock” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/11/30/insider-selling-loxo-oncology-inc-loxo-major-shareholder-sells-37500000-00-in-stock.html.

About Loxo Oncology

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Insider Buying and Selling by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Stock Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related stocks with our FREE daily email newsletter.